OCT (optical coherence tomography) is a non-invasive imaging test that uses light waves to create cross-sectional images of the retina, similar to ultrasound but using light instead of sound. The technology provides extremely detailed visualization of retinal layers — like a “biopsy” of the retina without actually taking tissue. Procedure: pupils may or may not be dilated; chin rest and forehead bar position the head; you stare at a fixation target; scanner captures images in 5-10 seconds per eye; computer generates cross-sectional views showing retinal layers; total appointment 15-30 minutes including dilation. Image resolution: 5-7 micrometers (much finer than ophthalmoscopy). Provides: layer-by-layer retinal anatomy; central retinal thickness measurements; macular volume; nerve fiber layer thickness; vitreoretinal interface assessment. Non-invasive nature makes it ideal for repeated monitoring. Central tool for diabetic macular edema (DME) management. Specific uses: diagnose DME (primary use — detects retinal thickening and intraretinal fluid before visible on standard exam); measure central retinal thickness (quantitative measurement; normal about 250 micrometers; DME defined as more than 300 micrometers in many studies); identify subretinal fluid (fluid beneath retina); detect intraretinal cysts (fluid-filled spaces); evaluate vitreomacular traction (pulling of vitreous on retina); identify epiretinal membrane (scar tissue on retinal surface); monitor treatment response (repeat OCT after anti-VEGF injections, laser, or steroids); distinguish edema causes (diabetic vs other — vein occlusion, age-related macular degeneration). Standard frequency: at diagnosis of DR; every 3-6 months if DME present; more frequently during active treatment. OCT increasingly replaces clinical exam alone for DME monitoring. OCT angiography (OCTA) — newer non-invasive extension that visualizes blood flow without dye injection. Technology: rapidly repeated OCT scans of same location; motion contrast detects blood flow (moving cells); generates depth-resolved vascular maps; no dye injection needed; about 5 seconds per eye. Advantages over fluorescein angiography (FA): no needle/IV; no dye reactions; no nausea or skin discoloration; can repeat as often as needed; layer-specific visualization (separate superficial and deep capillary plexus); shows foveal avascular zone clearly; faster procedure. Limitations: cannot show leakage (no dye to leak — only structural vasculature); limited field of view in many devices; image artifacts can occur; less established for guiding pan-retinal photocoagulation. Indications for OCTA in diabetes: evaluate macular capillary changes; monitor for neovascularization without dye; quantify foveal avascular zone (FAZ) enlargement (marker of DR severity); detect retinal nonperfusion. Increasingly used; not yet fully replaced FA.
OCT Uses in Diabetic Retinopathy
| Use | Application |
|---|---|
| Diabetic macular edema diagnosis | Primary indication; detects retinal thickening |
| Central retinal thickness measurement | Quantitative tracking |
| Subretinal fluid detection | Identifies fluid beneath retina |
| Treatment response monitoring | After anti-VEGF, laser, steroids |
| Vitreomacular interface | Detect traction, epiretinal membranes |
| Distinguish DR from other macular diseases | Different pattern recognition |
OCT vs Other Eye Imaging
| Test | What it shows | Invasiveness |
|---|---|---|
| OCT | Cross-sectional retinal anatomy | None (light only) |
| OCTA | Blood flow without dye | None |
| Fluorescein angiography | Vascular leakage and perfusion | IV dye injection |
| Color photography | 2D retinal surface | None |
| Ultrasound | Posterior eye through opaque media | Eye contact |
Diabetic Macular Edema Findings on OCT
- Increased central retinal thickness (greater than 300 micrometers usually).
- Intraretinal cysts (round dark spaces in retina).
- Subretinal fluid (fluid beneath retina).
- Hard exudates (bright spots — lipid deposits).
- Disorganization of retinal inner layers (DRIL — affects vision prognosis).
- Loss of foveal depression (when severe).
- Vitreomacular traction (if present).
Treatment Monitoring Pattern
- Baseline OCT before starting treatment.
- OCT 4-6 weeks after each anti-VEGF injection.
- Decision based on OCT findings: continue if edema persists; extend interval if improved; switch agent if no response.
- Stable disease: OCT every 3-6 months.
- Active treatment: OCT monthly often.
- Vision and OCT both considered in treatment decisions.
- Diabetes management critical — OCT improvements correlate with glycemic improvement.
When OCT Is Performed
- At diagnosis of diabetic retinopathy.
- Annually for mild non-proliferative DR.
- Every 6 months for moderate to severe non-proliferative DR.
- Every 3 months for proliferative DR or DME.
- Before and after anti-VEGF injections.
- Before and after laser treatment.
- Whenever vision changes occur.
- Pre-operative planning for vitreoretinal surgery.
The Bottom Line
OCT (optical coherence tomography) is a non-invasive imaging test that uses light waves to create cross-sectional images of the retina, similar to ultrasound but using light instead of sound. The technology provides extremely detailed visualization of retinal layers — like a “biopsy” of the retina without actually taking tissue. Procedure: pupils may or may not be dilated; chin rest and forehead bar position the head; you stare at a fixation target; scanner captures images in 5-10 seconds per eye; computer generates cross-sectional views showing retinal layers; total appointment 15-30 minutes including dilation. Image resolution: 5-7 micrometers (much finer than ophthalmoscopy). Provides: layer-by-layer retinal anatomy; central retinal thickness measurements; macular volume; nerve fiber layer thickness; vitreoretinal interface assessment. Central tool for diabetic macular edema (DME) management. Specific uses: diagnose DME (primary use — detects retinal thickening and intraretinal fluid before visible on standard exam); measure central retinal thickness (quantitative measurement; normal about 250 micrometers; DME defined as more than 300 micrometers in many studies); identify subretinal fluid; detect intraretinal cysts; evaluate vitreomacular traction; identify epiretinal membrane; monitor treatment response after anti-VEGF injections, laser, or steroids; distinguish edema causes (diabetic vs other — vein occlusion, age-related macular degeneration). Standard frequency: at diagnosis of DR; every 3-6 months if DME present; more frequently during active treatment. OCT increasingly replaces clinical exam alone for DME monitoring. OCT angiography (OCTA) — newer non-invasive extension that visualizes blood flow without dye injection. Technology: rapidly repeated OCT scans of same location; motion contrast detects blood flow; generates depth-resolved vascular maps; no dye injection needed; about 5 seconds per eye. Advantages over fluorescein angiography (FA): no needle/IV; no dye reactions; no nausea or skin discoloration; can repeat as often as needed; layer-specific visualization; shows foveal avascular zone clearly; faster procedure. Limitations: cannot show leakage (no dye to leak — only structural vasculature); limited field of view in many devices; image artifacts can occur; less established for guiding pan-retinal photocoagulation. Indications for OCTA in diabetes: evaluate macular capillary changes; monitor for neovascularization without dye; quantify foveal avascular zone (FAZ) enlargement (marker of DR severity); detect retinal nonperfusion. Increasingly used; not yet fully replaced FA. Procedure expectations: brief, comfortable, non-invasive; minimal preparation; eat normally; take medications; bring sunglasses if dilation expected; scan takes 5-10 seconds per eye; total appointment 15-30 minutes; no contact with eye; no pain; results discussed during same visit. Frequency for diabetes: every 6-12 months for stable retinopathy; every 1-3 months during active DME treatment. For adults with type 2 diabetes — OCT is essential tool for retinopathy monitoring; ask retina specialist about OCT findings at each visit. See our broader diabetic retinopathy guide for context.
